BD (Becton, Dickinson and Company) announced a 5.4% revenue increase in Q4 2026 to $5.3 billion, with GAAP and adjusted diluted EPS of $2.52 and $4.15, respectively. For fiscal year 2026, revenue rose 4.9% to $19.5 billion, and adjusted diluted EPS reached $12.70. The company highlighted a 30% increase in cash from continuing operations and a 42.5% rise in free cash flow. BD also issued guidance for fiscal 2027, expecting low single-digit revenue growth and adjusted diluted EPS between $13.10 and $13.30, reflecting confidence in its focused MedTech strategy and recent business transformations.
BDX holds a market cap of $56.98 billion on Pluang as of Nov 05, 2026 18:11 WIB, with a dividend yield of 2.01%. Despite the company's strong fiscal 2026 results and positive outlook for 2027, BDX shares are down 1.06% in the last day on Pluang, with a trading volume of 4,460,066. Investor sentiment on Pluang currently leans fully toward selling, reflecting cautious positioning amid the recent earnings report.
BD (Becton, Dickinson and Company) announced a 1% increase in its quarterly dividend to $1.06 per share, payable December 31, 2026. The company also authorized the repurchase of up to 10 million shares of its common stock, reflecting confidence in it...
BD (Becton, Dickinson and Company) has named Bridget Bagnato as the worldwide president of its Peripheral Intervention business unit, effective November 16. Bagnato will lead the unit's global strategy, operations, and commercial performance from Tem...
Emerson is expected to increase its dividend by 6.3–8.1%, marking 70 years of consecutive dividend growth. This increase is supported by the company's strategic shift towards higher-margin Intelligent Devices and Software & Control segments, which is...
